JP2006517109A - アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 - Google Patents

アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 Download PDF

Info

Publication number
JP2006517109A
JP2006517109A JP2006503535A JP2006503535A JP2006517109A JP 2006517109 A JP2006517109 A JP 2006517109A JP 2006503535 A JP2006503535 A JP 2006503535A JP 2006503535 A JP2006503535 A JP 2006503535A JP 2006517109 A JP2006517109 A JP 2006517109A
Authority
JP
Japan
Prior art keywords
antibody
seq
antibodies
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006503535A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006517109A5 (enExample
Inventor
ニコラス エフ． ランドルフィ，
直也 鶴下
ポール アール． ヒントン，
シャンカー クマー，
Original Assignee
プロテイン デザイン ラブス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロテイン デザイン ラブス インコーポレイテッド filed Critical プロテイン デザイン ラブス インコーポレイテッド
Publication of JP2006517109A publication Critical patent/JP2006517109A/ja
Publication of JP2006517109A5 publication Critical patent/JP2006517109A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2006503535A 2003-02-07 2004-02-06 アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用 Pending JP2006517109A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US44564003P 2003-02-07 2003-02-07
US53390103P 2003-12-30 2003-12-30
PCT/US2004/004176 WO2004068931A2 (en) 2003-02-07 2004-02-06 Amphiregulin antibodies and their use to treat cancer and psoriasis

Publications (2)

Publication Number Publication Date
JP2006517109A true JP2006517109A (ja) 2006-07-20
JP2006517109A5 JP2006517109A5 (enExample) 2007-03-29

Family

ID=32853408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006503535A Pending JP2006517109A (ja) 2003-02-07 2004-02-06 アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用

Country Status (5)

Country Link
US (2) US7223393B2 (enExample)
EP (1) EP1608684A2 (enExample)
JP (1) JP2006517109A (enExample)
CA (1) CA2515081A1 (enExample)
WO (1) WO2004068931A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
JP2009513515A (ja) * 2003-07-04 2009-04-02 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ストレス誘導性リガンド依存性ｅｇｆｒ活性化の阻害
JP2010505934A (ja) * 2006-10-11 2010-02-25 フージョン アンティボディーズ リミテッド 併用療法
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2023519007A (ja) * 2020-03-27 2023-05-09 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ａｒｅｇに対する抗体及びその用途

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP1449538A1 (en) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibition of TACE or amphiregulin for the modulation of EGF receptor signal transactivation
DE102004010050A1 (de) * 2004-03-02 2005-09-22 Bayer Healthcare Ag Spezifische monoklonale und polyklonale Antikörper für Repinotan und dessen ringoffene Form
CA2568427A1 (en) * 2004-05-27 2006-01-12 Tanox, Inc. Method for preventing and treating mast cell mediated diseases
WO2006023844A2 (en) * 2004-08-20 2006-03-02 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
PT1976877E (pt) 2005-11-30 2014-04-29 Abbvie Inc Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
CN117903302A (zh) 2005-11-30 2024-04-19 Abbvie 公司 抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
EP1968998A4 (en) * 2005-12-21 2010-01-27 Medimmune Llc AFFINITY-OPTIMIZED EPHA2-AGONISTIC ANTIBODIES AND METHODS FOR THEIR USE
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
NZ579520A (en) * 2007-03-13 2012-06-29 Univ Zuerich Monoclonal human tumor-specific antibody that bnids to ny-eso-1
JP2010235447A (ja) * 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk 炎症性サイトカインの抑制剤
CA2700701C (en) 2007-09-26 2020-12-29 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
CL2008002886A1 (es) 2007-09-26 2009-12-04 Chugai Pharmaceutical Co Ltd Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
WO2009072604A1 (ja) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha 抗nr10抗体、およびその利用
GB0807018D0 (en) 2008-04-17 2008-05-21 Fusion Antibodies Ltd Antibodies and treatment
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
WO2010137012A1 (en) 2009-05-25 2010-12-02 Ramot At Tel-Aviv University Ltd. Peptide therapy for amphiregulin mediated diseases
EP2481752B1 (en) 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
CN104744591B (zh) 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012043634A1 (ja) * 2010-09-29 2012-04-05 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
MX355060B (es) 2010-11-17 2018-04-03 Chugai Pharmaceutical Co Ltd Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea.
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013070433A1 (en) * 2011-11-09 2013-05-16 Albert Einstein College Of Medicine Of Yeshiva University Targeting an amphiregulin-derived cell surface neo-epitope
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
MX382731B (es) 2013-09-27 2025-03-13 Chugai Pharmaceutical Co Ltd Metodo para producir heteromultimeros de polipeptidos.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
EP4269440A3 (en) 2015-02-27 2024-02-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
IL237852A0 (en) * 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
MX2018007781A (es) 2015-12-28 2018-09-05 Chugai Pharmaceutical Co Ltd Metodo para promover la eficiencia de purificacion del polipeptido que contiene la region de fragmento cristalizable (fc).
WO2017159287A1 (ja) 2016-03-14 2017-09-21 中外製薬株式会社 癌の治療に用いるための細胞傷害誘導治療剤
EP3449940B1 (en) 2016-04-28 2025-11-19 Chugai Seiyaku Kabushiki Kaisha Antibody-containing preparation
IL299099B2 (en) 2016-06-27 2025-07-01 Univ California Cancer treatment combinations
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
BR112020008393A2 (pt) 2017-11-01 2020-11-03 Chugai Seiyaku Kabushiki Kaisha variante e isoforma de anticorpos com atividade biológica reduzida
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2021202798A1 (en) * 2020-04-02 2021-10-07 The United States Of America As Represented By The Secretary Of The Navy Antigen binding proteins to class 5 etec adhesins
US11933781B2 (en) 2020-12-09 2024-03-19 The Regents Of The University Of Colorado Fibrosis model and methods of use thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
CN118598996B (zh) * 2024-08-08 2024-11-01 康立泰生物医药(青岛)有限公司 一种抗人白介素8抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02104596A (ja) * 1988-01-25 1990-04-17 Oncogen アムフイレグリン
JP2000504206A (ja) * 1995-12-22 2000-04-11 イノジェネティックス・ナムローゼ・フェンノートシャップ 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物
WO2001045697A1 (en) * 1999-12-21 2001-06-28 Kanebo, Limited Skin external agents and drugs

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668629A (en) * 1980-07-18 1987-05-26 The Board Of Trustees Of Leland Stanford Jr. University Human hybridomas, precursors and products
US5115096A (en) 1988-04-15 1992-05-19 Oncogen Amphiregulin: a bifunctional growth modulating glycoprotein
US5262298A (en) 1989-05-12 1993-11-16 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Method to assess the ability of a substance to inhibit or stimulate keratinocyte autocrine factor production
WO1990014069A2 (en) 1989-05-12 1990-11-29 The State Of Oregon Acting By And Through The State Board Of Education On Behalf Of The Oregon Health Sciences University Keratinocyte autocrine factor
US5855885A (en) * 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
JPH10507362A (ja) 1994-10-14 1998-07-21 ブリストル−マイヤーズ スクイブ カンパニー Ｈｅｒ４ヒトレセプタチロシンキナーゼ
WO1999038972A2 (en) 1998-01-28 1999-08-05 Chiron Corporation Human genes and gene expression products ii
AU752730B2 (en) * 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
JP2003527861A (ja) * 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
US20030165831A1 (en) 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
WO2001096389A2 (en) 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1305450A2 (en) 2000-07-28 2003-05-02 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
US20020156263A1 (en) 2000-10-05 2002-10-24 Huei-Mei Chen Genes expressed in breast cancer
AU2002239717A1 (en) 2000-10-20 2002-06-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
NZ525336A (en) 2000-10-20 2006-03-31 Expression Diagnostics Inc Leukocyte expression profiling
WO2002077234A2 (en) 2000-10-31 2002-10-03 Diadexus, Inc. Compositions and methods relating to colon specific genes and proteins
US20030087855A1 (en) 2001-09-13 2003-05-08 Isis Pharmaceuticals Inc. Antisense modulation of protein kinase R expression
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
JP2004519247A (ja) 2001-03-20 2004-07-02 オーソ・クリニカル・ダイアグノスティックス・インコーポレーテッド 発現プロファイルおよび使用法
AU2002307466A1 (en) 2001-04-20 2002-11-05 Millennium Pharmaceutical, Inc. Method for detecting breast cancer cells
EP1483288A4 (en) 2001-05-11 2005-09-21 Genome Therapeutics Corp HBM VARIANTS MODULATING BONE MASS AND LIPID LEVELS
US20040248196A1 (en) 2001-08-03 2004-12-09 Adams Timothy Edward Methods of screening based on the egf receptor crystal structure

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02104596A (ja) * 1988-01-25 1990-04-17 Oncogen アムフイレグリン
JP2000504206A (ja) * 1995-12-22 2000-04-11 イノジェネティックス・ナムローゼ・フェンノートシャップ 新規形態のアンフィレグリン、その製造方法および使用方法、ならびにそれを含む組成物
WO2001045697A1 (en) * 1999-12-21 2001-06-28 Kanebo, Limited Skin external agents and drugs

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009513515A (ja) * 2003-07-04 2009-04-02 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ ストレス誘導性リガンド依存性ｅｇｆｒ活性化の阻害
JP2011084580A (ja) * 2003-07-04 2011-04-28 Max-Planck-Ges Zur Foerderung Der Wissenschaften Ev ストレス誘導性リガンド依存性ｅｇｆｒ活性化の阻害
JP2007135581A (ja) * 2005-10-20 2007-06-07 Japan Science & Technology Agency 自己免疫性血小板減少性紫斑病（ｉｔｐ）患者の血液細胞特異的遺伝子群
JP2010505934A (ja) * 2006-10-11 2010-02-25 フージョン アンティボディーズ リミテッド 併用療法
JP2013537424A (ja) * 2010-08-14 2013-10-03 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2017048194A (ja) * 2010-08-14 2017-03-09 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2023519007A (ja) * 2020-03-27 2023-05-09 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ａｒｅｇに対する抗体及びその用途
JP7564882B2 (ja) 2020-03-27 2024-10-09 ナショナル インスティテュート オブ バイオロジカル サイエンシズ，ベイジン Ａｒｅｇに対する抗体及びその用途

Also Published As

Publication number Publication date
US20080226632A1 (en) 2008-09-18
EP1608684A2 (en) 2005-12-28
WO2004068931A2 (en) 2004-08-19
CA2515081A1 (en) 2004-08-19
US7223393B2 (en) 2007-05-29
US20040210040A1 (en) 2004-10-21
WO2004068931A3 (en) 2005-03-24

Similar Documents

Publication Publication Date Title
US7223393B2 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
JP2006517109A5 (enExample)
US9855291B2 (en) Anti-kidney associated antigen 1 (KAAG1) antibodies
JP2021120382A (ja) 部位特異的抗体コンジュゲーション方法および組成物
JP7003036B2 (ja) グリコシル化ｐｄ－１に対して特異的な抗体およびその使用方法
KR102618312B1 (ko) 항muc16 항체 및 그의 용도
KR20170008202A (ko) 흑색종에 사용하기 위한 항-ｄｌｌ3 항체 및 약물 접합체
JP2016538318A (ja) 新規ｓｅｚ６モジュレーターおよび使用方法
JP2019516705A (ja) 神経内分泌移行のリスクのある腫瘍を治療するための抗ｄｌｌ３薬物コンジュゲート
US20080260740A1 (en) Anti-LFL2 Antibodies for the Diagnosis, Prognosis and Treatment of Cancer
AU2016316758B2 (en) Antibodies and assays for detection of CD37
JP2021503915A (ja) ヒト組織因子を標的とするヒト化抗体
WO2011054112A1 (en) Antibodies that specifically block the biological activity of kidney associated antigen 1
US12043671B2 (en) Antibodies targeting an amphiregulin-derived cell surface neo-epitope
JPWO2012124334A1 (ja) 抗体、乳がんの治療に用いられる医薬組成物、腫瘍検査方法、及び、腫瘍検査用試薬
HK1234432A (en) Antibodies that specifically block the biological activity of a tumor antigen
HK1234432A1 (en) Antibodies that specifically block the biological activity of a tumor antigen
HK1234432B (en) Antibodies that specifically block the biological activity of a tumor antigen
NZ626513B2 (en) Anti-cd98 antibodies and methods of use thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20070205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100112

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100617